Holt J A, Richards J S, Midgley A R, Reichert L E
Endocrinology. 1976 Apr;98(4):1005-13. doi: 10.1210/endo-98-4-1005.
This investigation was undertaken to determine whether prolactin might act as a luteotropic hormone in the rat by increasing the receptor for LH. Immature female rats were treated with 5 SC injections of oFSH beginning at 0900 h on day 25; luteinization was induced with a single SC injection of oLH at 1500 h on day 27. In this model, LH-receptor activity, assessed by specific binding of [125I]iodohCG to ovarian membrane fractions, increased steadily (greater than 7-fold) from day 27 to day 33; specific [125I]iodoprolactin binding rose greater than 3-fold between days 27 and 31. Serum progesterone measured at 1500 h rose from greater than 10 ng/ml on day 27 to greater than 130 ng/ml on day 34. 2-Bromo-alpha-ergocryptine (CB-154, [EC]; 35 mug) given 2 X/day beginning at the time of LH injection, blocked nocturnal increases in serum prolactin measured at 0200 h on days 29, 30, and 31, and resulted in reduced binding of [125I]iodohCG on days 31 and 33; serum progesterone was similarly reduced on days 31 and 34 in EC-treated rats. Simultaneous treatment with EC and prolactin completely reversed the effects of EC with regard to both binding of [125A]iodohCG and serum progesterone. Changes in ovarian uptake of [125I]iodohCG in vivo were similar to those of the in vitro experiments described above. EC and/or prolactin treatment did not affect binding of [125I]iodoprolactin. In summary, the data indicate that LH in the absence of prolactin can induce the formation of corpora lutea which have an increased number of prolactin receptors but which have a few LH receptors and a reduced capacity to produce progesterone. If prolactin is present during the early luteinization process, corpora lutea develop an increased capacity to bind LH and to produce progesterone. It is possible that the increase in LH-receptor and progesterone production occur as independent events both mediated by the luteotropic action of prolactin. Alternatively, LH receptor might be limiting for LH stimulation of progesterone production.
本研究旨在确定催乳素是否可能通过增加促黄体生成素(LH)受体而在大鼠中作为促黄体激素发挥作用。未成熟雌性大鼠于第25天09:00开始接受5次皮下注射卵泡刺激素(oFSH);于第27天15:00通过单次皮下注射促黄体生成素(oLH)诱导黄体化。在该模型中,通过[125I]碘人绒毛膜促性腺激素(iodohCG)与卵巢膜组分的特异性结合评估的LH受体活性,从第27天到第33天稳步增加(超过7倍);特异性[125I]碘催乳素结合在第27天和第31天之间增加超过3倍。在15:00测量的血清孕酮从第27天的大于10 ng/ml升至第34天的大于130 ng/ml。从LH注射时开始,每天2次给予2-溴-α-麦角隐亭(CB-154,[EC];35 μg),可阻断第29、30和31天02:00测量的血清催乳素夜间升高,并导致第31天和第33天[125I]碘人绒毛膜促性腺激素结合减少;在接受EC治疗的大鼠中,第31天和第34天血清孕酮也同样降低。同时用EC和催乳素治疗完全逆转了EC在[125A]碘人绒毛膜促性腺激素结合和血清孕酮方面的作用。体内[125I]碘人绒毛膜促性腺激素卵巢摄取的变化与上述体外实验相似。EC和/或催乳素治疗不影响[125I]碘催乳素的结合。总之,数据表明,在没有催乳素的情况下,LH可诱导黄体形成,这些黄体具有增加的催乳素受体数量,但LH受体较少且产生孕酮的能力降低。如果在黄体化早期过程中存在催乳素,黄体则会发展出增加的结合LH和产生孕酮的能力。有可能LH受体增加和孕酮产生增加是由催乳素的促黄体作用介导的两个独立事件。或者,LH受体可能是LH刺激孕酮产生的限制因素。